Skip to main content
UniHealth

Doctor search

Robert B Bhisitkul, MD

Ophthalmology · San Francisco

NPI 1831138676

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
12
2 carriers
Office
1
Since medical school
34 years
Stanford University School of Medicine, 1992

Offices

1 location · UCSF Medical Group Business Services · 1,533 clinicians in this group

Looking this up.

Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

12 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bhisitkul’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

12 of 12 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026

California Medical Board record

Licence G84511 · Current

Licensed to practise in California · since 1998 · expires 2028-03-31 · Stanford University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Ophthalmology - Ophthalmology

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.9 (3.79 to 6.02) · 7,590 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.3 to 14.4) · 2,019 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths139.4 (110.22 to 168.58) · 452 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.622BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.626BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.491BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,336 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.24 (0.58 to 1.9) · 4,689 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.89 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 85 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.1 · 132 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.6 · 454 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 618 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 380 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.7 · 5,000 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.06 to 0.38) · 15,965 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.05 to 0.35) · 17,859 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.85 (0 to 1.83) · 4,184 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2 (1.1 to 2.9) · 6,516 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.35 (4.49 to 10.21) · 3,989 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5 (3.22 to 6.77) · 4,087 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.95 (0.74 to 3.15) · 2,034 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.95 (0.63 to 1.28) · 15,431 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 399 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.899No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.689No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.224No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 156 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20 · 564 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits60.3 · 160 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.7 · 550 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits44.1 · 660 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 667 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (4.8 to 6.7) · 2,019 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6 · 421 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 107 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.3 to 17.1) · 3,247 casesNo differentJan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Patient survey stars by topic at UCSF Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at UCSF Medical Center
Room was "always" clean71%
Nurses "always" communicated well80%
Doctors "always" communicated well80%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night50%
"YES", patients would definitely recommend the hospital81%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$127,456

Medicare paid this office $127,456 for 464 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Injection of drug into eye128$32,801$91
Established patient complete exam of visual system212$17,635$67
Injection of drug into eye92$13,862$70
Imaging of retina301$13,104$23
Established patient complete exam of visual system140$7,474$48
See all 12 services
Every Original Medicare service billed
Injection of drug into eye128$32,801$91
Established patient complete exam of visual system212$17,635$67
Injection of drug into eye92$13,862$70
Imaging of retina301$13,104$23
Established patient complete exam of visual system140$7,474$48
Imaging of retina229$5,737$16
New patient complete exam of visual system37$3,084$83
New patient complete exam of visual system46$3,016$66
Established patient problem focused exam of visual system11$508$46
Extended exam of the back part of the eye with retinal drawing16$330$21
Extended exam of the back part of the eye with retinal drawing11$208$19
Extended exam of the back part of the eye with optic nerve drawing13$161$12

Procedures year by year

Procedures billed to Original Medicare by year
Procedure201920202021202220232024
Injection of drug into eye494467576516473561

Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.

Who their Medicare patients are

464 Original Medicare patients in 2024. Average age 76 · Under 65 6% · 85 and older 19% · Women 53% · Also on Medicaid 36% · Health risk score 1.61. Sicker patients than 9 in 10 peers; the typical ophthalmology clinician is at 1.16.

Conditions among them: High blood pressure 70% · Diabetes 36% · Chronic kidney disease 32% · Coronary heart disease 24% · Depression 21% · Cancer 16% · Atrial fibrillation 16% · Heart failure 15% · COPD 10% · Stroke 9% · Dementia 8%.

The office billed $1,396,510, Medicare allowed $175,629 and paid $127,456; for 2,127 services of 30 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20244642,127761.61$1,396,510$127,456
20234742,094761.58$1,348,766$125,974
20224782,154751.53$1,387,730$126,749
20214452,269761.62$1,630,115$140,147
20204121,825751.66$1,229,699$114,714
20195012,249751.70$1,344,959$133,063
20184982,235751.66$1,332,997$135,996
20174691,997751.69$1,234,313$130,540
20165162,098751.64$1,243,267$136,142
20155101,971741.61$1,241,484$142,366
20144481,749751.44$1,047,856$119,516
20133911,774751.42$1,112,527$134,797

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 8 services

Original Medicare services billed in 2023
Injection of drug into eye112$34,812$74
Established patient complete exam of visual system337$30,200$63
Imaging of retina389$18,084$21
New patient complete exam of visual system101$7,834$78
Extended exam of the back part of the eye with retinal drawing62$1,121$18
Established patient problem focused exam of visual system14$562$40
2d ultrasound scan of eye tissue and structures15$401$24
Extended exam of the back part of the eye with optic nerve drawing31$367$12

2022: 8 services

Original Medicare services billed in 2022
Injection of drug into eye124$41,264$80
Established patient complete exam of visual system322$28,809$62
Imaging of retina343$17,813$21
New patient complete exam of visual system102$7,957$78
Extended exam of the back part of the eye with retinal drawing73$1,358$19
Extended exam of the back part of the eye with optic nerve drawing62$647$10
2d ultrasound scan of eye tissue and structures15$593$27
Established patient problem focused exam of visual system12$465$39

2021: 8 services

Original Medicare services billed in 2021
Injection of drug into eye121$45,653$79
Established patient complete exam of visual system315$31,116$64
Imaging of retina334$18,420$21
New patient complete exam of visual system91$7,073$78
Established patient problem focused exam of visual system31$1,328$42
Extended exam of the back part of the eye with retinal drawing60$1,144$19
2d ultrasound scan of eye tissue and structures19$692$24
Extended exam of the back part of the eye with optic nerve drawing56$608$11

2020: 11 services

Original Medicare services billed in 2020
Injection of drug into eye99$32,388$85
Established patient complete exam of visual system249$18,590$59
Imaging of retina266$12,098$20
Injection of drug into eye70$8,701$100
Established patient complete exam of visual system71$5,392$73
New patient complete exam of visual system45$3,421$76
Imaging of retina111$3,057$24
Established patient problem focused exam of visual system40$1,974$45
Extended exam of the back part of the eye with retinal drawing38$790$20
Extended exam of the back part of the eye with optic nerve drawing27$333$12
Extended exam of the back part of the eye with retinal drawing11$215$20

2019: 8 services

Original Medicare services billed in 2019
Injection of drug into eye109$45,312$92
Established patient complete exam of visual system337$32,892$64
Imaging of retina347$16,695$21
New patient complete exam of visual system76$6,397$84
Examination of eye by ophthalmoscope with retinal drawing78$2,536$19
Established patient problem focused exam of visual system57$2,533$42
Examination of eye by ophthalmoscope with retinal drawing63$1,881$16
2d ultrasound scan of eye tissue and structures16$846$28

2018: 9 services

Original Medicare services billed in 2018
Established patient complete exam of visual system343$38,373$65
Injection of drug into eye108$36,542$89
Imaging of retina331$17,672$23
New patient complete exam of visual system86$7,299$85
Established patient problem focused exam of visual system64$3,085$42
Examination of eye by ophthalmoscope with retinal drawing59$2,080$19
Examination of eye by ophthalmoscope with retinal drawing49$1,258$15
2d ultrasound scan of eye tissue and structures18$960$40
New patient problem focused exam of visual system20$878$44

2017: 10 services

Original Medicare services billed in 2017
Injection of drug into eye104$37,279$89
Established patient complete exam of visual system326$33,551$65
Imaging of retina256$13,593$22
New patient complete exam of visual system63$5,335$85
Established patient problem focused exam of visual system85$4,551$44
Examination of eye by ophthalmoscope with retinal drawing57$1,705$17
Examination of eye by ophthalmoscope with retinal drawing37$1,195$19
2d ultrasound scan of eye tissue and structures13$1,141$48
New patient problem focused exam of visual system15$575$38
Exam of retinal blood vessels using a special camera after injection of a dye12$490$41

2016: 10 services

Original Medicare services billed in 2016
Injection of drug into eye110$39,152$92
Established patient complete exam of visual system316$29,331$67
Imaging of retina306$17,003$25
Established patient problem focused exam of visual system124$7,813$44
New patient complete exam of visual system73$6,122$84
2d ultrasound scan of eye tissue and structures24$1,790$45
Examination of eye by ophthalmoscope with retinal drawing44$1,358$18
Exam of retinal blood vessels using a special camera after injection of a dye14$1,235$44
Examination of eye by ophthalmoscope with retinal drawing38$1,093$16
New patient problem focused exam of visual system23$962$42

2015: 11 services

Original Medicare services billed in 2015
Injection of drug into eye96$33,751$90
Established patient complete exam of visual system322$28,682$66
Imaging of retina270$13,959$24
New patient complete exam of visual system116$9,753$84
Established patient problem focused exam of visual system105$8,405$44
Examination of eye by ophthalmoscope with retinal drawing63$1,862$19
Exam of retinal blood vessels using a special camera after injection of a dye15$1,204$45
2d ultrasound scan of eye tissue and structures17$1,102$50
Examination of eye by ophthalmoscope with retinal drawing22$610$18
Photography of the retina14$471$22
New patient problem focused exam of visual system11$464$42

2014: 8 services

Original Medicare services billed in 2014
Injection of drug into eye89$33,079$92
Established patient complete exam of visual system299$24,747$66
Imaging of retina263$14,358$25
Established patient problem focused exam of visual system102$9,162$47
New patient complete exam of visual system80$6,979$87
Exam of retinal blood vessels using a special camera after injection of a dye17$890$44
Examination of eye by ophthalmoscope with retinal drawing32$855$20
Examination of eye by ophthalmoscope with retinal drawing26$640$17

2013: 10 services

Original Medicare services billed in 2013
Injection of drug into eye86$33,520$91
Established patient complete exam of visual system250$21,225$65
Established patient problem focused exam of visual system141$15,504$45
Imaging of retina180$10,189$24
New patient complete exam of visual system84$6,398$76
Examination of eye by ophthalmoscope with retinal drawing34$985$17
Examination of eye by ophthalmoscope with retinal drawing31$930$17
Exam of retinal blood vessels using a special camera after injection of a dye20$821$37
2d ultrasound scan of eye tissue and structures13$688$46
Photography of the retina18$365$19

Medicaid work

$170,692 in 2024

Medicaid paid $170,692 for 767 billed services this clinician did in 2024, up to 43 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Intravitreal injection of a pharmacologic agent (separate procedure)312$145,486
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST130$12,890
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina325$12,316
Medicaid work by year
2024767343$170,692
2023869442$134,882
20221,072442$83,728
20211,468546$162,928
2020911441$102,861
20191,138442$84,443
20181,509449$93,795
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Intravitreal injection of a pharmacologic agent (separate procedure)287$106,582
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST205$17,202
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina365$10,154
OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST12$945

2022

Largest Medicaid services in 2022
Intravitreal injection of a pharmacologic agent (separate procedure)353$50,129
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST172$14,617
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina520$10,190
Aflibercept injection27$8,791

2021

Largest Medicaid services in 2021
Intravitreal injection of a pharmacologic agent (separate procedure)527$111,812
Aflibercept injection38$22,336
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST249$16,277
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina624$10,600
OFF/OP EST MAY X REQ PHY/QHP30$1,901

2020

Largest Medicaid services in 2020
Intravitreal injection of a pharmacologic agent (separate procedure)328$82,740
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina432$8,494
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST139$8,080
Aflibercept injection12$3,547

2019

Largest Medicaid services in 2019
Intravitreal injection of a pharmacologic agent (separate procedure)360$64,657
Aflibercept injection28$7,083
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina576$6,718
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST174$5,986

2018

Largest Medicaid services in 2018
Intravitreal injection of a pharmacologic agent (separate procedure)329$68,990
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST519$15,348
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina563$5,902
OFF/OP EST MAY X REQ PHY/QHP98$3,555

Drugs they prescribed that Part D paid

$14,926

Pharmacies billed $14,926 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 166) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.

102 generic and 64 brand-name prescriptions · $14,926 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Difluprednate16$980$61
Prednisolone Acetate12$921$77
Dorzolamide-Timolol23$523$23
Latanoprost51$483$9
Brimonidine14$177$13

Year by year

Part D prescribing by year
2024166500% (0)39%$14,926
2023157490% (0)36%$10,378
2022127360% (0)41%$12,451
2021233570% (0)46%$19,477
2020141460% (0)48%$9,444
2019158420% (0)44%$8,425
2018165450% (0)48%$10,920
2017209400% (0)38%$39,128
201617343None38%$10,525
2015115330% (0)56%$34,510
201413631None56%$17,192
2013145380% (0)54%$11,715

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 7 drugs

Part D drugs prescribed in 2023
Prednisolone Acetate23$1,776$77
Difluprednate11$1,625$148
Latanoprost40$977$24
Atropine Sulfate11$899$82
Dorzolamide-Timolol23$525$23
Brimonidine11$364$33
Polymyxin B Sul-Trimethoprim13$118$9

2022: 4 drugs

Part D drugs prescribed in 2022
Latanoprost42$1,178$28
Dorzolamide-Timolol22$1,134$52
Brimonidine13$1,055$81
Olopatadine14$598$43

2021: 7 drugs

Part D drugs prescribed in 2021
Brimonidine34$3,404$100
Betimol15$2,386$159
Prednisolone Acetate29$2,004$69
Dorzolamide-Timolol36$1,419$39
Latanoprost35$1,139$33
Olopatadine12$526$44
Dorzolamide11$331$30

2020: 6 drugs

Part D drugs prescribed in 2020
Prednisolone Acetate20$1,599$80
Atropine Sulfate16$1,547$97
Dorzolamide-Timolol21$861$41
Brimonidine18$735$41
Latanoprost18$642$36
Polymyxin B Sul-Trimethoprim17$157$9

2019: 7 drugs

Part D drugs prescribed in 2019
Durezol15$2,931$195
Prednisolone Acetate21$1,600$76
Atropine Sulfate14$1,356$97
Latanoprost21$430$20
Dorzolamide-Timolol11$293$27
Polymyxin B Sul-Trimethoprim20$185$9
Brimonidine12$147$12

2018: 5 drugs

Part D drugs prescribed in 2018
Durezol14$2,489$178
Brimonidine27$1,367$51
Prednisolone Acetate18$993$55
Latanoprost23$307$13
Dorzolamide-Timolol12$229$19

2017: 6 drugs

Part D drugs prescribed in 2017
Brimonidine24$2,638$110
Prednisolone Acetate22$1,581$72
Latanoprost44$539$12
Dorzolamide-Timolol27$412$15
Polymyxin B Sul-Trimethoprim13$100$8
Timolol Maleate15$98$7

2016: 3 drugs

Part D drugs prescribed in 2016
Prednisolone Acetate18$1,239$69
Latanoprost26$354$14
Polymyxin B Sul-Trimethoprim16$127$8

2015: 3 drugs

Part D drugs prescribed in 2015
Patanol11$2,647$241
Prednisolone Acetate20$1,929$96
Latanoprost21$237$11

2014: 6 drugs

Part D drugs prescribed in 2014
Brimonidine17$1,746$103
Travatan Z11$1,215$110
Prednisolone Acetate12$1,178$98
Dorzolamide-Timolol12$315$26
Latanoprost12$178$15
Polymyxin B Sul-Trimethoprim11$104$9

2013: 2 drugs

Part D drugs prescribed in 2013
Prednisolone Acetate30$833$28
Polymyxin B Sul-Trimethoprim21$227$11

Money from drug and device companies

$5,679 in 2025

Industry payments by year
202524$5,400$5,679
2024510None$1,336
202345$4,200$4,433
202244None$3,127
202123None$2,571
201923None$372

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Sun Pharmaceutical IndustriesNone$5,400
1 payment
  • Consulting · 2025-09-18 · $5,400
Regeneron Healthcare SolutionsEylea Hd$279
3 payments
  • Meals for Eylea Hd · 2025-11-15 · $118
  • Meals for Eylea Hd · 2025-10-02 · $28
  • Meals for Eylea Hd · 2025-02-05 · $134
See all 4 published payments
Every published payment
Regeneron Healthcare SolutionsMeals · 2025-11-15Eylea Hd$118
Regeneron Healthcare SolutionsMeals · 2025-10-02Eylea Hd$28
Sun Pharmaceutical IndustriesConsulting · 2025-09-18None$5,400
Regeneron Healthcare SolutionsMeals · 2025-02-05Eylea Hd$134
See earlier years (2024, 2023, 2022, 2021, 2019)

2024: $1,336

Payments by company in 2024
Alcon VisionConstellation$417
3 payments
  • Meals for Constellation · 2024-09-25 · $139
  • Meals for Constellation · 2024-09-11 · $143
  • Meals for Constellation · 2024-07-17 · $135
Harrow EyeIheezo$349
3 payments
  • Meals for Iheezo · 2024-10-19 · $117
  • Meals for Triesence · 2024-10-19 · $117
  • Meals · 2024-10-19 · $115
Dutch Ophthalmic USAEva, Combined Machine$327
2 payments
  • Meals for Eva, Combined Machine · 2024-08-29 · $166
  • Meals for Eva, Combined Machine · 2024-01-30 · $162
Bausch & Lomb AmericasXipere$139
1 payment
  • Meals for Xipere · 2024-05-03 · $139
Apellis PharmaceuticalsSyfovre$103
1 payment
  • Meals for Syfovre · 2024-06-28 · $103

2023: $4,433

Payments by company in 2023
Genentech USAVabysmo$4,310
2 payments
  • Consulting for Vabysmo · 2023-11-02 · $4,200
  • Meals for Vabysmo · 2023-06-23 · $110
Apellis PharmaceuticalsSyfovre$74
1 payment
  • Meals for Syfovre · 2023-06-23 · $74
Astellas Pharma USNone$25
1 payment
  • Meals · 2023-10-14 · $25
Regeneron Healthcare SolutionsEylea$24
1 payment
  • Meals for Eylea · 2023-06-01 · $24

2022: $3,127

Payments by company in 2022
Alcon VisionNone$2,804
1 payment
  • Travel · 2022-08-06 · $2,804
Genentech USAVabysmo$126
1 payment
  • Meals for Vabysmo · 2022-06-25 · $126
Regeneron Healthcare SolutionsEylea$116
1 payment
  • Meals for Eylea · 2022-12-14 · $116
Alimera SciencesIluvien$81
1 payment
  • Meals for Iluvien · 2022-09-19 · $81

2021: $2,571

Payments by company in 2021
Alcon VisionNone$2,450
2 payments
  • Travel · 2021-07-31 · $2,049
  • Meals · 2021-07-31 · $401
Regeneron Healthcare SolutionsEylea$121
1 payment
  • Meals for Eylea · 2021-07-13 · $121

2019: $372

Payments by company in 2019
Genentech USALucentis$261
2 payments
  • Meals · 2019-07-27 · $148
  • Meals for Lucentis · 2019-04-29 · $112
Alcon VisionNone$111
1 payment
  • Meals · 2019-10-12 · $111

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2022Their institution$159,407
Genentech, Inc. · Port Delivery System for Ranibizumab · 2019Their institution$103,652
Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2021Their institution$88,015
Genentech, Inc. · Port Delivery System for Ranibizumab · 2021Their institution$81,293
Genentech, Inc. · Port Delivery System for Ranibizumab · 2020Their institution$80,018
Genentech, Inc. · Port Delivery System of Ranizibumab Extension Study · 2019Their institution$41,617
Genentech, Inc. · Lucentis Fsv4 Lad Amd Ladder · 2019Their institution$41,047
Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2024Their institution$39,910
Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2023Their institution$33,473
Genentech, Inc. · Port Delivery System of Ranizibumab Extension Study · 2020Their institution$32,613
Genentech, Inc. · Port Delivery System of Ranizibumab Extension Study · 2021Their institution$23,390
ABBVIE INC. · Long-Term Follow-Up Study of Rgx-314 and Fellow Eye Substudy (Rgx-314 Srltfu) · 2025Their institution$14,664
Genentech, Inc. · Lucentis Fsv4 Lad Amd Ladder · 2020Their institution$13,025
F. Hoffmann-La Roche AG · Clinical Trial Versus Real-World Outcomes With Anti-Vascular Endothelial Growth Factor Therapy for Central Retinal Vein Occlusion · 2020This clinician$6,979
Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2025Their institution$5,742
ABBVIE INC. · Long-Term Follow-Up Study of Rgx-314 and Fellow Eye Substudy · 2025Their institution$2,222
F. Hoffmann-La Roche AG · Heterogeneity Among Patients With Retinal Vein Occlusion Relationship Between Injection Need and Vision Outcomes With As-Needed Ranibizumab · 2022This clinician$1,604
F. Hoffmann-La Roche AG · Clinical Trial Versus Real-World Outcomes With Anti-Vegf Therapy for Central Retinal Vein Occlusion · 2020This clinician$850

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
75.0 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1831138676
Licence
CA G84511California G84511: Current · expires 2028-03-31
Trained
Stanford University School of Medicine, 1992 · 34 years ago
Gender
Male
More record details
Sole proprietor
No
Medicaid ID
CA 00G845110
Taxonomy
Federal specialty code 207W00000X (207W00000X)
Mailing address
1635 Divisadero Street, Suite 625, Box 1821, San Francisco, CA, 94143
NPI first listed
2006-06-06
NPI last updated
2008-07-21

This is when the NPI record was last certified, not a medical board exam.